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Summary
Purpose: Loss of PTEN, which is common in glioblastoma multiforme (GBM), results in activation of the mammalian
target of rapapmycin (mTOR), thereby increasing mRNA translation of a number of key proteins required for cell-cycle
progression. CCI-779 is an inhibitor of mTOR. The primary objectives of this study were to determine the efficacy of
CCI-779 in patients with recurrent GBM and to further assess the toxicity of the drug. Experimental Design: CCI-779 was
administered weekly at a dose of 250 mg intravenously for patients on enzyme-inducing anti-epileptic drugs (EIAEDs).
Patients not on EIAEDs were initially treated at 250 mg; however, the dose was reduced to 170 mg because of intolerable
side effects. Treatment was continued until unacceptable toxicity, tumor progression, or patient withdrawal. The primary
endpoint was 6-month progression-free survival. Results: Forty-three patients were enrolled; 29 were not on EIAEDs. The
expected toxicity profile of increased lipids, lymphopenia, and stomatitis was seen. There were no grade IV hematological
toxicities and no toxic deaths. One patient was progression free at 6 months. Of the patients assessable for response, there
were 2 partial responses and 20 with stabilization of disease. The median time to progression was 9 weeks. Conclusions:
CCI-779 was well tolerated at this dose schedule; however, there was no evidence of efficacy in patients with recurrent
GBM. Despite initial disease stabilization in approximately 50% of patients, the durability of response was short. Because
of the low toxicity profile, CCI-779 may merit exploration in combination with other modalities.
Introduction
Novel therapeutic strategies are needed for the treat-
ment of patients with recurrent glioblastoma multiforme
(GBM), for whom the median survival is currently 4
to 6 months. Recent advances in the understanding of
aberrant molecular and cytogenetic pathways involved in
GBM pathogenesis and progression have led to the ra-
tional targeting of some of these pathways. A significant
percentage of GBM have altered PTEN gene suppres-
sion activity [1], which results in the increased activity
of the phosphotidylinositol 3-kinase (PI3K)/Akt pathway.
The PI3K/Akt pathway activates the mammalian target of
rapamycin (mTOR), increasing translation of a number
of key proteins required for cell-cycle progression. The
presence of PTEN gene alterations and the subsequent
activation of these downstream pathways have been as-
sociated with poor prognosis in anaplastic astrocytoma,
anaplastic oligodendroglioma, and GBM [2–4]. Restora-
tion of PTEN function or targeting of the components of
the PI3K/Akt/mTOR pathways can result in cell-cycle ar-
rest, apoptosis, or reduced tumorigenicity and are rational
targets for clinical evaluation.
CCI-779 is a dihydroxymethyl propionic acid ester
of the immunosuppressive agent sirolimus (rapamycin,
Rapamune©R) that targets the mTOR pathway. CCI-779
binds to FKBP-12 to form a complex that interacts with
mTOR, which results in cell-cycle arrest by means of inhi-
bition of RNA translation [5–7]. CCI-779 is lipid soluble
and inhibits the growth of a number of human tumor lines
in nude mouse models, including GBM [8]. Based on
these promising pre-clinical studies, there was an interest
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in evaluating this novel agent in patients with recurrent
GBM.
There is increasing evidence that brain tumor patients
receiving P450 enzyme-inducing anti-epileptic drugs
(EIAEDs) have markedly altered pharmacokinetics, re-
sulting in accelerated drug metabolism. CCI-779 and ra-
pamycin are substrates for the cytochrome P450 isoen-
zyme 3A4. A North American Brain Tumor Consortium
phase I study established the maximum tolerated dose of
CCI-779 in patients with malignant glioma who are taking
EIAEDs at 250 mg [9].
We report on the results of a phase II study of CCI-779
in patients with recurrent GBM. The primary objectives
of this study were to determine the efficacy (defined by
6-month progression-free survival) of patients with recur-




Patients at least 18 years of age were eligible for partic-
ipation if they had histopathologically confirmed GBM
with recurrence documented by neuroimaging. Patients
were also eligible if they had a prior low-grade glioma
and a subsequent histological confirmation of GBM. Pa-
tients must have relapsed after prior treatment with radi-
ation therapy, with an interval of at least 4 weeks from
treatment with radiation therapy, and could not have un-
dergone treatment for more than 2 prior relapses. Patients
were required to have a Karnofsky Performance Scale
(KPS) score of at least 60, an estimated survival of >8
weeks, hematologic, renal, and hepatic status within the
normal ranges, levels of cholesterol <350 mg/dl, and lev-
els of triglyceride <400 mg/dl. No exclusions were made
based on gender, race, minority status, or economic sta-
tus. Female patients were not pregnant or nursing, and
all patients (both men and women) agreed to practice
birth control during and for 3 months after completing the
study. Patients or their surrogates signed an institutionally
approved Committee on Human Research consent form.
Patients did not have any serious intercurrent illness or
disease that obscured or altered drug metabolism.
Study design
Patients were treated with CCI-779 as a 30-minute intra-
venous (IV) infusion weekly with no rest period required.
For the purpose of evaluation, a cycle was defined as ev-
ery 4 weeks. Because of the documented side effect of
lipid elevation, allowance for the use of lipid-lowering
agents was incorporated into the phase II study. After ev-
ery 2 cycles of treatment, patients underwent re-staging
with neuro-imaging and clinical evaluation including neu-
rological examination and assessment of corticosteroid
use. Determination of tumor status was made using stan-
dard criteria [10]. Therapy with CCI-779 was continued
as long as the tumor was stable or smaller in size and
the patient was clinically stable or improved on stable or
decreasing corticosteroid doses. Treatment continued in-
definitely as long as there were no unacceptable toxicities,
patient refusal to continue participation, or tumor progres-
sion. For all patients, the initial phase II dose was 250 mg
IV weekly. Toxicities were graded according to the NCI
Common Toxicity Criteria (CTC Version 2.0) scale.
Statistical considerations
Enrollment of 32 patients would give a 92% probabil-
ity of successfully detecting a 35% 6-month progression
free-survival (PFS) rate and a 90% probability of re-
jecting the drug if the 6-month progression-free survival
(PFS) rate was 15% or less. The study would be consid-
ered worth pursuing if at least 8/32 patients had 6-month
progression-free survival.
Results
Forty-three patients were enrolled (65% male). All pa-
tients enrolled had primary GBM. The median age was
48 years (range 26–71 years) and the median KPS was 90.
Patients’ characteristics are shown in Table 1. For patients
not on EIAEDS, the initial dose was 250 mg weekly; how-
ever, this was reduced to 170 mg weekly in many patients
because of intolerable side effects (stomatitis). Thirteen
patients were treated at 250 mg and 16 patients at 170 mg.
The 14 patients on EIAEDs were treated at 250 mg. The
major toxicities observed were elevation in lipid profiles,
lymphopenia, and stomatitis (Table 2). Twenty-one pa-
tients were started on lipid-lowering agents during the
study; none were on lipid-lowering agents at the time of
enrollment. There were no grade IV hematological toxi-
cities and no toxic deaths.
Two patients were lost to follow-up and were censored
for the endpoint of progression-free survival. Of the 41
evaluable patients, only 1 patient was progression free at
6 months. There were 2 partial responses and 20 patients
who had stabilization of disease; however, the median
time to progression was short, at 9 weeks. The Kaplan
Meier estimate for time to progression is shown in Fig-
ure 1.
Discussion
Mutations of the PTEN gene result in constitutive ac-
tivation of the PI3K pathway, resulting in increased
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Table 1. Patients’ characteristics
Patients taking Patients taking
NEIAEDs (N = 29) EIAEDs (N = 14)




90–100 13 (44.8%) 4 (28.6%)
≤80 16 (55.2%) 10 (71.4%)
Sex
Female 10 (34.5%) 5 (35.7%)
Male 19 (65.5%) 9 (64.3%)
Race
Black 2 (6.9%) 0 (0%)
White 27 (93.1%) 14 (100%)
Prior Chemotherapy
Regimens
0 2 (6.9%) 0 (0%)
1 22 (75.9%) 9 (64.3%)
2 2 (6.9%) 5 (35.7%)
3 3 (10.3%) 0 (0%)
Table 2. Grade III and IV toxicities observed (n = 43 pa-
tients) using the National Cancer Institute common toxicity grad-
ing system




Elevated cholesterol 9 7
Elevated triglyceride 5 5
proliferation, dysregulation of the cell cycle, and resis-
tance to chemotherapy-induced apoptosis. This is rele-
vant in glioma therapy, as PTEN mutations are present in
approximately 40% to 60% of all GBM, and alterations
Figure 1. Kaplan Meier estimate for time to progression for 41 patients with recurrent GBM treated with CCI-779.
in PTEN are of prognostic significance [1]. One of the
downstream pathways of PTEN involves mTOR, which
is inhibited by CCI-779. Based on preclinical data on CCI-
779, which showed potential antiglioma activity, we eval-
uated this agent in patients with recurrent GBM. Because
CCI-779 and rapamycin are metabolized by the p450 hep-
atic enzyme system, and concurrent use of EIAEDs may
result in increased clearance of CCI-779, the appropri-
ate phase II dose in patients on enzyme-inducing anti-
epileptic agents was established first [9]. The agent was
well tolerated, with side effects as described at a similar
dosing schedule in solid cancers [11].
This phase II study sought to evaluate the efficacy of
CCI-779 as defined by 6-month progression-free survival
in patients with recurrent GBM irrespective of the use
of EIAEDs. Unfortunately, despite good tolerance of the
agent, CCI-779 did not demonstrate sufficient antitumor
activity to warrant further study as a single agent. There
are possibly several reasons for this lack of efficacy. Al-
though the pharmacokinetic results suggested adequate
systemic concentrations of the drug to block mTOR [9],
actual drug concentration within the tumors had not been
documented. The presence of the blood-brain barrier and
inadequate penetration of the agent to the infiltrative tu-
mor cells may be a barrier for drug delivery. This em-
phasizes the challenges of performing clinical trials of
novel agents in patients with malignant glioma [12]. A
small pilot study being performed by the North Ameri-
can Brain Tumor Consortium involves 10 patients who
will be administered CCI-779 prior to planned surgical
resection of a recurrent malignant glioma. In addition to
evaluation of inhibition of mTOR, measurements of tumor
drug levels are planned and may help in answering this
question.
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PTEN status of the tumors at the time of enrollment
was not required or mandated. As with any ‘targeted’
therapy, enrollment of patients lacking the specific ge-
netic abnormality may cause underestimation of the true
efficacy of the agent. This poses a significant challenge in
the selection of patients, given the invasive nature of tis-
sue acquisition. Retrospective analysis of tissue samples
is also fraught with potential for misinterpretation, as the
specimens analyzed tend to be representative of the tumor
at the time of initial diagnosis and not at the time of recur-
rence following therapy with radiation and/or chemother-
apy. Changes in the molecular targets could theoretically
occur with time, and the most informative sample would
be at the time of treatment with the targeted agent.
It is well accepted that many cell-signaling pathways
overlap, and there may actually be an interdependence of
activity within these pathways. Targeting only one aspect
of a pathway may be successful in proof-of-principle stud-
ies; however, this may unfortunately not translate into a
benefit of clinical significance for the patient. An example
of this is the recent demonstration of the alterations in cy-
clin D1/c-myc expression as critical determinants of cell
sensitivity to mTOR inhibitors, which suggested that ex-
cessive transcription of these genes in tumors may inhibit
the effectiveness of mTOR inhibitors [13]. Other rela-
tionships between signaling molecules have been demon-
strated in vivo by Choe et al., using human GBM tissue mi-
croarrays [14]. In addition to the well-accepted relation-
ship of the PTEN and PI3K pathways, the authors show
correlation of PTEN with the family of forkhead tran-
scription factors as well as the mutant epidermal growth
factor receptor vIII. Others have also described the re-
lationship of epidermal growth factor receptor (EGFR)
with this particular signaling pathway [15]. This is partic-
ularly relevant for GBM, as frequent mutation of EGFR
is seen and is known to confer an unfavorable prognosis
[16]. There may be a scientific rationale for the combi-
nation of EGFR inhibitors with mTOR inhibitors given
these findings. These studies also suggest that the signal-
ing abnormalities specific to the individual patient may be
important information for stratification into clinical trials
of these targeted agents.
In addition to these reasons for the limited efficacy of
CCI-779 observed in this study, potential mechanisms of
resistance to rapamycin and its analogs include mutation
of the binding proteins FKBP-12, alteration of the down-
stream effectors of mTOR, and mutation of mTOR itself
[17, 18]. Many of these mechanisms are being elucidated,
but their clinical significance needs to be further studied.
It is anticipated that many of these cytostatic agents
that target specific signaling pathways are unlikely to have
durable control of tumor growth as single agents because
of the reasons described above. There is the danger of
discarding a potentially useful agent that could be used
in combined modality therapy because of its lack of ef-
ficacy as a single agent. Preclinical data support the use
of mTOR inhibitors in combination with radiation and
chemotherapy [19–21]. The current paradigm of evaluat-
ing the efficacy of these drugs as single agents first rather
than in combination with radiation therapy, chemother-
apy, or other targeted therapies may inherently delay ap-
propriate use of these novel compounds. Given that the
agent is well tolerated, proceeding with the study of these
combinations may be worthy of further study.
Conclusions
This phase II study of CCI-779 in patients with recurrent
GBM on and off enzyme-inducing anti-epileptic drugs
failed to demonstrate any efficacy as a single agent. Be-
cause CCI-779 was well tolerated, further combination
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